243 results on '"Lipton, Richard B."'
Search Results
2. A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults
3. The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
4. Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials
5. Plasma calcitonin gene–related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion
6. Migraine screening in English and Spanish
7. Priority acute and preventive migraine treatment benefits: Results of the Migraine Clinical Outcome Assessment System (MiCOAS) qualitative study of people living with migraine
8. Patient‐reported experiences with migraine‐related cognitive symptoms: Results of the MiCOAS qualitative study
9. Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo‐controlled study
10. Predictors of treatment‐response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti‐inflammatory drugs in acute treatment of episodic migraine
11. Longitudinal assessment of comorbidities and co‐occurring conditions in adolescents with migraine: A secondary analysis of the National Longitudinal Study of Adolescent to Adult Health (Add Health)
12. Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine
13. The unique role of stigma in migraine‐related disability and quality of life
14. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial
15. Short‐term stroke risk after emergency department treat‐and‐release headache visit
16. AVP‐825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial
17. Faster Improvement in Migraine Pain Intensity and Migraine‐Related Disability at Early Time Points with AVP‐825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study
18. Framingham‐Based Cardiovascular Risk Estimates Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study
19. Sexual Dysfunction in Women With Migraine and Overweight/Obesity: Relative Frequency and Association With Migraine Severity
20. Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study
21. Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study
22. Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention
23. Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States
24. Do behavioral treatments work for migraine prevention?
25. Impact of the COVID‐19 pandemic on people living with migraine: Results of the MiCOAS qualitative study
26. Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials
27. Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study
28. Development and validation of a novel patient‐reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary
29. The value of the patient perspective in understanding the full burden of migraine
30. Learning the full impact of migraine through patient voices: A qualitative study
31. Chronic versus episodic migraine: The 15‐day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency
32. Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome
33. Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study
34. Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study
35. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study
36. Between and within‐woman differences in the association between menstruation and migraine days
37. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study
38. Systematic review of outcomes and endpoints in preventive migraine clinical trials
39. Systematic review of outcomes and endpoints in acute migraine clinical trials
40. Evaluation of the 6‐item Identify Chronic Migraine screener in a large medical group
41. The migraine signature study: Methods and baseline results
42. Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study
43. Smartphone‐Delivered Progressive Muscle Relaxation for the Treatment of Migraine in Primary Care: A Randomized Controlled Trial
44. Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study
45. Predicting the Future of Migraine Attack Prediction
46. Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study
47. Patterns of Perceived Stress Throughout the Migraine Cycle: A Longitudinal Cohort Study Using Daily Prospective Diary Data
48. Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT‐6) Total and Item‐Specific Scores in Chronic Migraine
49. The Effect of Psychiatric Comorbidities on Headache‐Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
50. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.